JAK抑制剂与TNF抑制剂在类风湿关节炎中的安全性:来自香港生物制剂登记处的真实世界数据
该回顾性分析基于香港生物制剂登记处2008—2021年数据,纳入1732例曾使用JAK抑制剂或TNF抑制剂的类风湿关节炎患者,比较主要不良心血管事件、癌症及感染发生率。调整混杂因素后,JAK抑制剂组主要不良心血管事件和癌症风险与TNF抑制剂组无显著差异,但感染发生率显著更高,尤其是带状疱疹。
要点
- JAK抑制剂组主要不良心血管事件调整后HR为1.36(95%CI 0.62, 2.96),与TNF抑制剂组无显著差异。
- JAK抑制剂组癌症调整后HR为0.87(95%CI 0.39, 1.95),与TNF抑制剂组无显著差异。
- JAK抑制剂组感染发生率显著高于TNF抑制剂组(16.3 vs 9.9/100患者年,P=0.02),带状疱疹尤为明显。
核心结论
- 在真实世界环境中,与TNF抑制剂相比,JAK抑制剂使用者主要不良心血管事件或癌症风险未见增加。
- 但JAK抑制剂使用者非严重感染(包括带状疱疹)的发生率增加。
研究设计与样本
- 回顾性分析香港生物制剂登记处2008—2021年数据。
- 纳入曾使用JAK抑制剂或TNF抑制剂的类风湿关节炎患者,共2471个治疗疗程(JAK抑制剂n=551,TNF抑制剂n=1920),涉及1732例患者(女性83.7%,年龄53.8[12.5]岁;随访6431患者年)。
主要发现
- JAK抑制剂组与TNF抑制剂组分别发生15例和40例主要不良心血管事件(发生率1.34 vs 0.75/100患者年;P=0.22)。
- 两组癌症发生率无显著差异(JAK抑制剂0.81 vs TNF抑制剂0.85/100患者年;P=0.25)。
- JAK抑制剂组主要不良心血管事件调整后HR为1.36(95%CI 0.62, 2.96)(P=0.44),癌症调整后HR为0.87(95%CI 0.39, 1.95)(P=0.74)。
- JAK抑制剂组感染发生率显著高于TNF抑制剂组(16.3 vs 9.9/100患者年;P=0.02),带状疱疹发生率亦显著更高(3.49 vs 0.94/100患者年;P<0.001)。
- JAK抑制剂使用者年龄显著更大、动脉粥样硬化危险因素更多、既往恶性肿瘤频率更高。
关键数值与推荐
- 主要不良心血管事件调整后HR 1.36(95%CI 0.62, 2.96),P=0.44,JAK抑制剂组 vs TNF抑制剂组。
- 癌症调整后HR 0.87(95%CI 0.39, 1.95),P=0.74,JAK抑制剂组 vs TNF抑制剂组。
- 感染发生率16.3 vs 9.9/100患者年(JAK抑制剂组 vs TNF抑制剂组),P=0.02。
- 带状疱疹发生率3.49 vs 0.94/100患者年(JAK抑制剂组 vs TNF抑制剂组),P<0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the incidence of major adverse cardiovascular events (MACEs), cancer and infective complications in RA patients using Janus kinase (JAKis) and TNF (TNFis) inhibitors. METHOD: A retrospective analysis of data from the Hong Kong Biologics Registry 2008-2021 was performed. RA patients who had ever used JAKis or TNFis were included. The incidence of MACEs, cancer and infections were compared between the two groups, with adjustment for confounding factors. RESULTS: A total of 2471 courses of JAKis (n = 551) and TNFis (n = 1920) were used in 1732 RA patients (83.7% women, age 53.8 [12.5] years; follow-up 6431 patient-years). JAKi users had significantly older age, more atherosclerotic risk factors and higher frequency of past malignancies. A total of 15 and 40 MACEs developed in the JAKi and TNFi users, respectively (incidence 1.34 vs 0.75 per 100 patient-years; P = 0.22). There was no significant difference in the incidence of cancers between the two groups (0.81 [JAKi] vs 0.85 [TNFi] per 100 patient-years; P = 0.25). The adjusted hazard ratios of MACE and cancer in the JAKi users were 1.36 (95% CI: 0.62, 2.96) (P = 0.44) and 0.87 (95% CI: 0.39, 1.95) (P = 0.74), respectively. Rates of infections were significantly higher in the JAKi than TNFi users (16.3 vs 9.9 per 100 patient-years; P = 0.02), particularly herpes zoster (3.49 vs 0.94 per 100 patient-years; P < 0.001). CONCLUSIONS: In a real-life setting, there is no increase in MACEs or cancers in users of JAKis compared with TNFis. However, the incidence of non-serious infections, including herpes zoster, was increased in users of JAKis.
引用
- Mok CC, So H, Yim CW, et al. Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry. Rheumatology (Oxford). 2024. PMID: 37129549. doi:10.1093/rheumatology/kead198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。